Canaccord raised the firm’s price target on Travere Therapeutics to $23 from $18 and keeps a Buy rating on the shares. The firm noted Filspari was granted FDA full approval for the treatment of IgAN which together with the updated label, expanded the indication for Filspari to now all patients with IgAN who are at risk for disease progression.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere upgraded to Buy at Guggenheim after IgAN approval, ahead of FSGS updates
- Travere Therapeutics upgraded to Buy from Neutral at Guggenheim
- Broadcom AI results fail to enthuse the Street: Morning Buzz
- Travere Therapeutics price target raised to $23 from $14 at Citi
- Ligand, Travere Therapeutics receives full FDA approval for Filspari